Alisertib (Standard)
Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 95%
- No. CAS: 1028486-01-2
- Fòrmula: C27H20ClFN4O4
- Peso molecular:518.92
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-70044
GSK-1070916Aurora B/C Inhibitor -
HY-10127
BarasertibAurora B Inhibitor -
HY-10161
TozasertibAurora A/B/C Inhibitor -
HY-10126
Barasertib-HQPAAurora B Inhibitor -
HY-13252
MK-5108Aurora Kinase Inhibitor -
HY-12054
HesperadinAurora B Inhibitor -
HY-10128
ZM-447439Aurora A/B Inhibitor -
HY-10329
JNJ-7706621Aurora Kinase/CDK Inhibitor -
HY-14711
ReversineAutophagy Inducer -
HY-10804
CCT 137690Apoptosis Inducer -
HY-13253
AMG 900Aurora Kinase Inhibitor
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 1028486-01-2
-
Peso molecular 518.92
-
Fòrmula C27H20ClFN4O4
-
SMILES
O=C(C1=CC=C(C=C1OC)NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(C=CC=C5F)OC)O
-
Synonyms
MLN 8237 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Güllü G, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood June 24, 2010 vol. 115 no. 25 5202-5213. [Content Brief]
[2]. Sloane DA, et al. Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237 ACS Chem. Biol., 2010, 5 (6), pp 563-576. [Content Brief]
[3]. Bavetsias V, et al. Aurora Kinase Inhibitors: Current Status and Outlook. Front Oncol. 2015 Dec 21;5:278. [Content Brief]
[4]. Manfredi MG, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.Clin Cancer Res. 2011 Dec 15;17(24):7614-7624. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Alisertib (Standard) Related Classifications
HY-10971R Related Classifications
Powered by Bioz